Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia

February 25, 2021 Auto Bot Collaborates, Develop, Liquid Biopsy, MedTech, Qiagen 0

Shots:

  • The companies collaborated to develop liquid biopsy-based CDx based on NGS technology to complement Inovio’s therapies. The collaboration initially focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from VGX-3100
  • QIAGEN’s bioinformatic expertise will raise the predictive biomarker power in Inovio’s patient selection. The assay will now be developed for use on the Illumina NextSeq 550Dx platform
  • VGX-3100 is a late-stage DNA immunotherapy, currently in two P-III trials (REVEAL 1 & 2) and has the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: NBC 7 San Diego

The post Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia first appeared on PharmaShots.